Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000460691 | SCV000559468 | benign | Acute myeloid leukemia | 2025-01-20 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002256307 | SCV002531762 | benign | Hereditary cancer-predisposing syndrome | 2020-09-06 | criteria provided, single submitter | curation | |
Breakthrough Genomics, |
RCV004717634 | SCV005314362 | benign | not provided | criteria provided, single submitter | not provided | ||
Ambry Genetics | RCV004975552 | SCV005558656 | likely benign | Inborn genetic diseases | 2024-10-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003942547 | SCV004762756 | likely benign | CEBPA-related disorder | 2019-11-08 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |